Tag - KALA

Developments

Kala Pharma reports positive results from Phase 3 dry eye disease trial

Kala Pharmaceuticals’ (NASDAQ:KALA) EYSUVIS met both primary efficacy endpoints in a Phase 3 trial for the short-term treatment of dry eye disease. The trial, called STRIDE 3, demonstrated a statistically significant...

March 9, 2020

Developments

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

Kala Pharmaceuticals (NASDAQ:KALA) completed enrollment in its STRIDE 3 Phase 3 clinical trial of EYSUVIS for the short-term treatment of dry eye disease. The trial’s inclusion/exclusion criteria have been modified from...

January 15, 2020

Tag - KALA

Kala Pharma reports positive results from Phase 3 dry eye disease trial

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

General

More